These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
596 related articles for article (PubMed ID: 31595147)
1. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma. Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147 [TBL] [Abstract][Full Text] [Related]
2. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction. Tan Z; Lei Y; Xu J; Shi S; Hua J; Zhang B; Meng Q; Liu J; Zhang Y; Wei M; Yu X; Liang C Aging (Albany NY); 2020 Nov; 12(23):24228-24241. PubMed ID: 33226369 [TBL] [Abstract][Full Text] [Related]
3. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Hu Y; Chen Y Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315 [TBL] [Abstract][Full Text] [Related]
4. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360 [TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer survival analysis defines a signature that predicts outcome. Raman P; Maddipati R; Lim KH; Tozeren A PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011 [TBL] [Abstract][Full Text] [Related]
6. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma. Chen D; Huang H; Zang L; Gao W; Zhu H; Yu X Front Immunol; 2021; 12():728062. PubMed ID: 34691034 [TBL] [Abstract][Full Text] [Related]
7. Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma. Peng T; Sun F; Yang JC; Cai MH; Huai MX; Pan JX; Zhang FY; Xu LM World J Gastroenterol; 2024 May; 30(19):2575-2602. PubMed ID: 38817665 [TBL] [Abstract][Full Text] [Related]
8. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma. Han Y; Drobisch P; Krüger A; William D; Grützmann K; Böthig L; Polster H; Seifert L; Seifert AM; Distler M; Pecqueux M; Riediger C; Plodeck V; Nebelung H; Weber GF; Pilarsky C; Kahlert U; Hinz U; Roth S; Hackert T; Weitz J; Wong FC; Kahlert C J Hematol Oncol; 2023 Feb; 16(1):7. PubMed ID: 36737824 [TBL] [Abstract][Full Text] [Related]
9. Construction of a prognostic prediction system for pancreatic ductal adenocarcinoma to investigate the key prognostic genes. Zheng B; Peng J; Mollayup A; Bakri A; Guo L; Zheng J; Xu H Mol Med Rep; 2018 Jan; 17(1):216-224. PubMed ID: 29115420 [TBL] [Abstract][Full Text] [Related]
10. Prognostic Implications of an Autophagy-related Gene Signature in Pancreatic Ductal Adenocarcinoma. Liu WS; Feng YX; Li SN; Shao YJ; Wang K Am J Clin Oncol; 2022 Mar; 45(3):95-104. PubMed ID: 35195559 [TBL] [Abstract][Full Text] [Related]
11. Correlation of laminin subunit alpha 3 expression in pancreatic ductal adenocarcinoma with tumor liver metastasis and survival. Xing Y; Jing X; Qing G; Jiang Y Radiol Oncol; 2024 Jun; 58(2):234-242. PubMed ID: 38452390 [TBL] [Abstract][Full Text] [Related]
12. A 15-Inflammation-Related Gene Signature Predicts the Prognosis of Patients With Pancreatic Ductal Adenocarcinoma. Sun X; Song H; Sun X; Liao C; Wang G; Xu Y; Li L; Han Y; Xu C; Wang W; Cai S; Liang H; Yu H Cancer Invest; 2024 Mar; 42(3):226-242. PubMed ID: 38616304 [TBL] [Abstract][Full Text] [Related]
13. A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma. Li A; Ye B; Lin F; Wang Y; Miao X; Jiang Y Precis Clin Med; 2022 Jun; 5(2):pbac010. PubMed ID: 35694712 [TBL] [Abstract][Full Text] [Related]
14. Development and validation of a cancer stem cell-related signature for prognostic prediction in pancreatic ductal adenocarcinoma. Feng Z; Shi M; Li K; Ma Y; Jiang L; Chen H; Peng C J Transl Med; 2020 Sep; 18(1):360. PubMed ID: 32958051 [TBL] [Abstract][Full Text] [Related]
15. Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma. Song J; Xu Q; Zhang H; Yin X; Zhu C; Zhao K; Zhu J J Cell Biochem; 2018 Jun; 119(6):4559-4569. PubMed ID: 29239017 [TBL] [Abstract][Full Text] [Related]
16. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data. Zhou YJ; Zhu GQ; Zhang QW; Zheng KI; Chen JN; Zhang XT; Wang QW; Li XB DNA Cell Biol; 2019 Nov; 38(11):1207-1222. PubMed ID: 31483163 [TBL] [Abstract][Full Text] [Related]
17. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648 [TBL] [Abstract][Full Text] [Related]
18. A New Stemness-Related Prognostic Model for Predicting the Prognosis in Pancreatic Ductal Adenocarcinoma. Huang XY; Qin WT; Su QS; Qiu CC; Liu RC; Xie SS; Hu Y; Zhu SY Biomed Res Int; 2021; 2021():6669570. PubMed ID: 34671679 [TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNAs expressed in pancreatic ductal adenocarcinoma and lncRNA BC008363 an independent prognostic factor in PDAC. Li J; Liu D; Hua R; Zhang J; Liu W; Huo Y; Cheng Y; Hong J; Sun Y Pancreatology; 2014; 14(5):385-90. PubMed ID: 25200694 [TBL] [Abstract][Full Text] [Related]
20. Development and validation of a metastasis-related Gene Signature for predicting the Overall Survival in patients with Pancreatic Ductal Adenocarcinoma. Wu M; Li X; Liu R; Yuan H; Liu W; Liu Z J Cancer; 2020; 11(21):6299-6318. PubMed ID: 33033514 [No Abstract] [Full Text] [Related] [Next] [New Search]